GSK to buy US cancer biotech IDRx for up to US$1.15 billion

GSK to buy US cancer biotech IDRx for up to US.15 billion

GSK agreed to buy US biotech IDRx for as much as US$1.15 billion to gain new cancer medicines.  The UK drugmaker will pay US$1 billion upfront for IDRx, whose lead drug for gastrointestinal tumours shows potential against mutations that currently leave patients with few treatment options, GSK said on Monday (Jan 13).  IDRx’s experimental medicine…

Read More

Smart glasses enter new era with sleeker designs, lower prices

Smart glasses enter new era with sleeker designs, lower prices

PRODUCERS of hi-tech connected eyewear are multiplying their innovations with increasingly discreet models in an attempt to make a difference in a highly competitive – and fast-emerging – market. Live translation, GPS, cameras: glasses are quickly adopting new functionalities. “There are so many of these smart wearables, and more of them are going on your…

Read More

Top Asian oil buyers in turmoil after sweeping Russian sanctions

Top Asian oil buyers in turmoil after sweeping Russian sanctions

REFINERS, tanker operators, traders and port executives across Asia were scrambling on Monday (Jan 13) to manage the fallout from the US’s most aggressive sanctions on Russia’s oil industry to date, and the impact on major importers China and India. The two countries have been the main beneficiaries of cut-price Russian crude since the invasion…

Read More